Figure 6.
DDR1 inhibitor 7rh enhances antitumor activity of RG7787 in A431/H9 and pancreatic cancer KLM1 xenograft tumor models. Female athymic nude mice were subcutaneously injected with A) A431/H9 or B) KLM1 tumor cells. When tumors reached 100–120mm3, mice were treated with vehicle, 7rh alone, RG7787 alone, or a combination of 7rh and RG7787. 7rh (20mg/kg) was given daily by oral gavage starting on day 5 (indicated by small arrows) for a total of 16 doses. RG7787 (75 μg) was administered by intravenous tail injection every other day starting on day 6 for a total of eight doses, as indicated by long arrows. Each data point represents average of mean tumor volume of 4–7 mice per group that are followed over time from the day of inoculation. Statistically significant difference in tumor volume was observed between mice treated with RG7787 alone compared to the mice treated with the combination starting from day 8 and this difference was maintained during the course of experiment. Results shown are representative of more than two similar experiments.